Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• JossonSMatsuokaYChungLWZhauHEWangRTumor-stroma co-evolution in prostate cancer progression and metastasisSemin Cell Dev Biol2010211263219948237
   PubMed Web of Science ®Google Scholar
• ArmstrongAJMarengoMSOlteanSCirculating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markersMol Cancer Res201198997100721665936
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• ArmstrongAJGarrett-MayerESYangYCde WitRTannockIFEisenbergerMA contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysisClin Cancer Res200713216396640317975152
   PubMed Web of Science ®Google Scholar
• ArmstrongAJGarrett-MayerEOu YangYCProstate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancerJ Clin Oncol200725253965397017761981
   PubMed Web of Science ®Google Scholar
• ArmstrongAJGarrett-MayerEde WitRTannockIEisenbergerMPrediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancerClin Cancer Res201016120321120008841
   PubMed Web of Science ®Google Scholar
• HalabiSVogelzangNJKornblithABPain predicts overall survival in men with metastatic castration-refractory prostate cancerJ Clin Oncol200826152544254918487572
   PubMed Web of Science ®Google Scholar
• TannockIFOsobaDStocklerMRChemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsJ Clin Oncol1996146175617648656243
   PubMed Web of Science ®Google Scholar
• RoqueIFMMartinez-ZapataMJScott-BrownMAlonso-CoelloPRadioisotopes for metastatic bone painCochrane Database Syst Rev20117CD00334721735393
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFEffect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM studyJ Clin Oncol201230Suppl 5 Abstr LBA1
   Web of Science ®Google Scholar
• de BonoJFizaziKSaadFPrimary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitorJ Clin Oncol201230Suppl Abstr 4519
   Google Scholar
• Enzalutamide (XTANDI Capsules) [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2012 [updated September 4, 2012]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htmAccessed December 12, 2012
   Google Scholar
• LogothetisCDe BonoJSMolinaAEffect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III studyJ Clin Oncol201129Suppl Abstr 4520
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRLong-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancerJ Natl Cancer Inst2004961187988215173273
   PubMed Web of Science ®Google Scholar
• AdamADixonAKAllisonDJGraingerRGGrainger and Allison’s Diagnostic Radiology: a Textbook of Medical Imaging5th edEdinburghChurchill Livingstone2008
   Google Scholar
• LewingtonVJMcEwanAJAckeryDMA prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to boneEur J Cancer19912789549581716935
   PubMed Web of Science ®Google Scholar
• BuchaliKCorrensHJSchuererMSchnorrDLipsHSydowKResults of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinomaEur J Nucl Med1988147–83493512460352
   PubMedGoogle Scholar
• PorterATMcEwanAJPoweJEResults of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancerInt J Radiat Oncol Biol Phys19932558058138478230
   PubMed Web of Science ®Google Scholar
• QuiltyPMKirkDBolgerJJA comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancerRadiother Oncol199431133407518932
   PubMed Web of Science ®Google Scholar
• OosterhofGORobertsJTde ReijkeTMStrontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary GroupEur Urol200344551952614572748
   PubMed Web of Science ®Google Scholar
• SerafiniANHoustonSJRescheIPalliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trialJ Clin Oncol1998164157415819552068
   PubMed Web of Science ®Google Scholar
• SartorOReidRHHoskinPJSamarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancerUrology200463594094515134985
   PubMed Web of Science ®Google Scholar
• SartorOReidRHBushnellDLQuickDPEllPJSafety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone painCancer2007109363764317167764
   PubMed Web of Science ®Google Scholar
• MorrisMJPandit-TaskarNCarrasquilloJPhase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerJ Clin Oncol200927152436244219364960
   PubMed Web of Science ®Google Scholar
• TuSMMillikanREMengistuBBone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trialLancet2001357925333634111210994
   PubMed Web of Science ®Google Scholar
• SciutoRFestaAReaSEffects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trialJ Nucl Med2002431798611801708
   PubMed Web of Science ®Google Scholar
• FizaziKBeuzebocPLumbrosoJPhase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancerJ Clin Oncol200927152429243519364971
   PubMed Web of Science ®Google Scholar
• ParkerCHeinrichDO’SullivanJMOverall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha- pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastasesJ Clin Oncol201230Suppl 5 Abstr 8
   Web of Science ®Google Scholar
• BayerRadium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone MetastasesClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated September 20, 2012]. Available from: http://clinicaltrials.gov/show/NCT01516762. NLM identifier: NCT01516762Accessed November 1, 2012
   Google Scholar
• PerezCAPrinciples and Practice of Radiation Oncology4th edPhiladelphiaLippincott Williams & Wilkins2004
   Google Scholar
• BrulandØSNilssonSFisherDRLarsenRHHigh-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?Clin Cancer Res20061220 Pt 26250s6257s17062709
   PubMed Web of Science ®Google Scholar
• BlakeGMGrayJMZivanovicMAMcEwanAJFlemingJSAckeryDMStrontium-89 radionuclide therapy: a dosimetric study using impulse response function analysisBr J Radiol1987607156856923620827
   PubMed Web of Science ®Google Scholar
• BreenSLPoweJEPorterATDose estimation in strontium-89 radiotherapy of metastatic prostatic carcinomaJ Nucl Med1992337131613231613572
   PubMed Web of Science ®Google Scholar
• ASBMR educational materials [webpage on the Internet]Bone curriculum Available from: http://depts.washington.edu/bonebio/ASBMRed/ASBMRed.htmlAmerican Society of Bone and Mineral Research [updated 2008]Accessed July 26, 2012
   Google Scholar
• TiepoltCGruningTFrankeWGRenaissance of 224 Ra for the treatment of ankylosing spondylitis: clinical experiencesNucl Med Commun2002231616611748439
   PubMed Web of Science ®Google Scholar
• NilssonSLarsenRHFossaSDFirst clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastasesClin Cancer Res200511124451445915958630
   PubMed Web of Science ®Google Scholar
• RitterMACleaverJETobiasCAHigh-LET radiations induce a large proportion of non-rejoining DNA breaksNature19772665603653655859634
   PubMed Web of Science ®Google Scholar
• HallEJGiacciaAJRadiobiology for the Radiologist6th edPhiladelphiaLippincott Williams & Wilkins2006
   Google Scholar
• HenriksenGFisherDRRoeskeJCBrulandOSLarsenRHTargeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in miceJ Nucl Med200344225225912571218
   PubMed Web of Science ®Google Scholar
• HenriksenGBreistolKBrulandOSFodstadOLarsenRHSignificant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases modelCancer Res200262113120312512036923
   PubMed Web of Science ®Google Scholar
• SmelandSEriksteinBAasMSkovlundEHessSLFossaSDRole of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized studyInt J Radiat Oncol Biol Phys20035651397140412873686
   PubMed Web of Science ®Google Scholar
• NilssonSBalteskardLFossaSDPhase I study of Alpharadin2 (223Ra), and a-emitting bone-seeking agent in cancer patients with skeletal metastasesEurJ Nucl Med Mol Imaging200431S2S290 Abstract 370
   Google Scholar
• CarrasquilloJADonoghueJAOPandit-TaskarNPhase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to boneJ Clin Oncol20102815s Abstr 4680
   Google Scholar
• NilssonSFranzenLParkerCBone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studyLancet Oncol20078758759417544845
   PubMed Web of Science ®Google Scholar
• NilssonSStrangPAksnesAKA randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancerEur J Cancer201248567868622341993
   PubMed Web of Science ®Google Scholar
• BubleyGJCarducciMDahutWEligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupJ Clin Oncol199917113461346710550143
   PubMed Web of Science ®Google Scholar
• NilssonSFranzénLParkerCAlpha-emitting radium-223: Two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancerEur J Cancer Suppl20097411 Abstract P-7018
   Web of Science ®Google Scholar
• NilssonSO’Bryan-TearCGBolstadBLoknaAParkerCAlkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with Radium-223 (Alpharadin™)J Clin Oncol201129Suppl Abstr 4620
   Google Scholar
• CleelandCSRyanKMPain assessment: global use of the Brief Pain InventoryAnn Acad Med Singapore19942321291388080219
   PubMedGoogle Scholar
• Palliative Care: Symptom Management and End-of-Life CareGenevaWorld Health Organization2004 Available from: http://www.who.int/3by5/publications/documents/en/genericpalliativecare082004.pdf. Accessed
   Google Scholar
• AlgetaASAA Dose Finding Study of Radium-223 for Prostate Cancer Patients with Bone MetastasesClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated September 8, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00337155. NLM identifier: NCT00337155Accessed November 1, 2012
   Google Scholar
• FleischHBisphosphonates: mechanisms of actionEndocr Rev1998191801009494781
   PubMed Web of Science ®Google Scholar
• RyanCJShahSEfstathiouEPhase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseClin Cancer Res201117144854486121632851
   PubMed Web of Science ®Google Scholar
• SartorAOHeinrichDHelleSIRadium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)J Clin Oncol201230Suppl 5 Abstr 9
   Web of Science ®Google Scholar
• LoblawAMiteraGMalignant extradural spinal cord compression in men with prostate cancerCurr Opin Support Palliat Care20115320621021725245
   PubMedGoogle Scholar
• RyanCJSmithMRDe BonoJSInterim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)J Clin Oncol201230Suppl Abstr LBA4518
   Google Scholar
• Medivation IncA Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer (PREVAIL)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated October 11, 2012]. Available from: http://clinicaltrials.gov/show/NCT01212991. NLM identifier: NCT01212991Accessed November 1, 2012
   Google Scholar
• ItalianoAOrtholanCOudardSDocetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancerEur Urol20095561368137518706755
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRSobanFde WitREisenbergerMTannockIFDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyJ Clin Oncol200826224224518182665
   PubMed Web of Science ®Google Scholar
• NekollaEAKellererAMKuse-IsingschulteMEderESpiessHMalignancies in patients treated with high doses of radium-224Radiat Res1999152Suppl 6S3S710564925
   PubMed Web of Science ®Google Scholar
• KossmanSEWeissMAAcute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostateCancer200088362062410649256
   PubMed Web of Science ®Google Scholar
• SaylorPJLeeRJSmithMREmerging therapies to prevent skeletal morbidity in men with prostate cancerJ Clin Oncol201129273705371421860001
   PubMed Web of Science ®Google Scholar
• Bristol-Myers SquibbRandomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer (READY)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated October 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00744497. NLM identifier: NCT00744497Accessed November 1, 2012
   Google Scholar
• HussainMSmithMRSweeneyCCabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trialJ Clin Oncol201129Suppl Abstr 4516
   PubMed Web of Science ®Google Scholar
• Exelixis Study of Cabozantinib (XL184) Versus Prednisone in Men with Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone or MDV3100 (COMET-1)ClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated October 2, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01605227. NLM identifier: NCT01605227Accessed November 1, 2012
   Google Scholar
• Exelixis Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated October 11, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01522443. NLM identifier: NCT01522443Accessed November 1, 2012
   Google Scholar
• AlgetaASAA Study of Alpharadin® with Docetaxel in Patients with Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated May 11, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01106352. NLM identifier: NCT01106352Accessed November 1, 2012
   Google Scholar
• DeWeeseTLSongDYCurrent evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostateUrology200055216917410688072
   PubMed Web of Science ®Google Scholar
• Quadramet^® (samarium Sm 153 lexidronam injection) [prescribing information]Langhorne, PAEUSA Pharma (USA) Inc2009
   Google Scholar
• Metastron™ (strontium-89 chloride injection) [prescribing information]Arlington Heights, ILGE Healthcare2006
   Google Scholar